<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infection</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Tobias</forename><surname>Mueller</surname></persName>
							<email>tobias.mueller@charite.de</email>
							<affiliation key="aff0">
								<orgName type="institution">Medizinische Klinik m. S. Hepatologie und Gastroenterologie</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum</addrLine>
									<settlement>Charit e -Universit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Janett</forename><surname>Fischer</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Sektion Hepatologie</orgName>
								<orgName type="department" key="dep2">Klinik und Poliklinik f€ ur Gastroenterologie und Rheumatologie</orgName>
								<orgName type="institution">Universit€ atsklinikum</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Reinhard</forename><surname>Gessner</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Klinik f€ ur Visceral</orgName>
								<address>
									<addrLine>Transplantations-, Thorax-und Gef€ aßchirurgie</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Universit€ atsklinikum Leipzig</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jonas</forename><surname>Rosendahl</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">Martin Luther University</orgName>
								<address>
									<settlement>Halle</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephan</forename><surname>B€ Ohm</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Sektion Hepatologie</orgName>
								<orgName type="department" key="dep2">Klinik und Poliklinik f€ ur Gastroenterologie und Rheumatologie</orgName>
								<orgName type="institution">Universit€ atsklinikum</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Florian</forename><surname>Van B€ Ommel</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Sektion Hepatologie</orgName>
								<orgName type="department" key="dep2">Klinik und Poliklinik f€ ur Gastroenterologie und Rheumatologie</orgName>
								<orgName type="institution">Universit€ atsklinikum</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Viola</forename><surname>Knop</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Medizinische Klinik I</orgName>
								<orgName type="institution" key="instit1">Universit€ atsklinikum</orgName>
								<orgName type="institution" key="instit2">Johann Wolfgang-Goethe Universit€ at</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Sarrazin</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Medizinische Klinik I</orgName>
								<orgName type="institution" key="instit1">Universit€ atsklinikum</orgName>
								<orgName type="institution" key="instit2">Johann Wolfgang-Goethe Universit€ at</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Heiko</forename><surname>Witt</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Kinderklinik und Poliklinik</orgName>
								<orgName type="institution">Technische Universit€ at M€ unchen (TUM)</orgName>
								<address>
									<addrLine>M€ unchen</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Mas Marques</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Robert Koch-Institut</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Kovacs</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution" key="instit1">IFB Adiposity Diseases</orgName>
								<orgName type="institution" key="instit2">Leipzig University Medical Center</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dorit</forename><surname>Schleinitz</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution" key="instit1">IFB Adiposity Diseases</orgName>
								<orgName type="institution" key="instit2">Leipzig University Medical Center</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Stumvoll</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution" key="instit1">IFB Adiposity Diseases</orgName>
								<orgName type="institution" key="instit2">Leipzig University Medical Center</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Bl€ Uher</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution" key="instit1">IFB Adiposity Diseases</orgName>
								<orgName type="institution" key="instit2">Leipzig University Medical Center</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Bugert</surname></persName>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Institute of Transfusion Medicine and Immunology</orgName>
								<orgName type="department" key="dep2">Medical Faculty Mannheim</orgName>
								<orgName type="institution" key="instit1">Heidelberg University</orgName>
								<orgName type="institution" key="instit2">German Red Cross Blood Service of Baden-W€ urttemberg-Hessen</orgName>
								<address>
									<settlement>Mannheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eckart</forename><surname>Schott</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">Medizinische Klinik m. S. Hepatologie und Gastroenterologie</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum</addrLine>
									<settlement>Charit e -Universit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Berg</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Sektion Hepatologie</orgName>
								<orgName type="department" key="dep2">Klinik und Poliklinik f€ ur Gastroenterologie und Rheumatologie</orgName>
								<orgName type="institution">Universit€ atsklinikum</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Med</forename><forename type="middle">Tobias</forename><surname>Mueller</surname></persName>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Charit e-Universit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infection</title>
					</analytic>
					<monogr>
						<idno type="ISSN">1478-3223</idno>
					</monogr>
					<idno type="MD5">608503832AB13AF0505FF49F555CDEFD</idno>
					<idno type="DOI">10.1111/liv.13094</idno>
					<note type="submission">Received 29 October 2015; Accepted 29 January 2016 Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1111/liv.13094/suppinfo Liver International (2016)</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:34+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>LDL, low-density lipoprotein</term>
					<term>LDLR, low-density lipoprotein receptors</term>
					<term>SNP, single nucleotide polymorphism</term>
					<term>VLDL, very low-density lipoproprotein hepatic fibrosis -hepatic steatosis -lipoprotein -low-density lipoprotein receptor -spontaneous HCV resolution</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background &amp; Aims: Infectious hepatitis C virus (HCV) particles bind to host lipoproteins such as low-density lipoproteins (LDLs).</s><s>Low-density lipoprotein receptors (LDLR) have been termed candidate receptors for HCV-LDL complexes.</s><s>Functional host genetic single nucleotide polymorphisms (SNPs) in the apolipoprotein E (APOE) gene encoding apolipoprotein E (apoE) a major structural LDL component and natural ligand of LDLRlikely influence the course of HCV infection.</s><s>We investigated the prevalence of APOE SNPs in two large and independent cohorts of patients with chronic HCV infection compared to respective controls.</s><s>Methods: We genotyped 996 chronically HCV-infected patients; 179 patients with spontaneous HCV clearance; 283 individuals with non-HCV-associated liver disease; and 2 234 healthy controls.</s><s>Results: APOE genotype proportions in patients with persistent HCV infection significantly differed from healthy controls (P = 0.007) primarily because of a substantial under-representation of APOE4 alleles in chronically HCV-infected patients (10.2%) compared to 13.0% in healthy controls (P = 0.001).</s><s>The distribution of APOE4 allele positive genotypes (e2e4, e3e4, e4e4) also significantly differed between chronically HCV-infected patients and healthy controls (1.4%, 17%, 1% vs. 2.4%, 20.5%, 1.7%; P = 0.001), suggesting a protective effect of the APOE4 allele in HCV infection.</s><s>This was confirmed by a significant overrepresentation of the APOE4 allele in patients with spontaneous HCV clearance (17.6%;</s><s>P = 0.00008).</s><s>The APOE4 allele distribution in patients with non-HCV-associated liver disease (14.0%) was very similar to healthy controls and also differed from chronically HCV-infected patients (P = 0.012), suggesting HCV specificity.</s><s>Conclusions: Our findings suggest that the APOE4 allele may confer a protective effect in the course of HCV infection.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Infectious hepatitis C virus (HCV) particles bind to plasma lipoproteins such as very low-density lipoproteins (VLDLs) and low-density lipoproteins (LDLs) <ref type="bibr" target="#b0">(1)</ref><ref type="bibr" target="#b1">(2)</ref><ref type="bibr" target="#b2">(3)</ref>.</s><s>Hepatic internalization of such viruslipoprotein complexes is mediated by low-density lipoprotein receptors (LDLR) <ref type="bibr" target="#b3">(4)</ref><ref type="bibr" target="#b4">(5)</ref><ref type="bibr" target="#b5">(6)</ref>.</s><s>Apolipoprotein E (protein) (ApoE), a structural component of LDLs and natural ligand of LDLR, is also integrally linked to plasma lipoprotein metabolism <ref type="bibr" target="#b6">(7)</ref>.</s><s>The three major isoforms of apoE (apoE2, E3 and E4) are decoded by three alleles (APOE epsilon 2, 3 and 4).</s><s>The most common isoform apoE3 was labelled the wild type apoE.</s><s>ApoE2, E3 and E4 differ in their amino sequence at positions 112 and 158.</s><s>At these different sites, apoE2 contains cysteine/cysteine, apoE3 cysteine/arginine and apoE4 arginine/arginine.</s></p><p><s>There is growing evidence that functional host-specific genetic polymorphisms within APOE influence on the interaction between the host and HCV, and therefore affect the natural and treatment-induced course of HCV infection <ref type="bibr" target="#b7">(8)</ref>.</s><s>APOE single nucleotide polymorphisms have been associated with an increased likelihood of persistent HCV infection <ref type="bibr" target="#b8">(9)</ref> and severity of consecutive histological liver damage <ref type="bibr" target="#b9">(10)</ref>.</s><s>We previously associated APOE with treatment outcomes following standard combination therapy in chronic HCV infection <ref type="bibr" target="#b10">(11)</ref>.</s><s>Other studies linked APOE with the risk of treatment-induced psychiatric side effects in these patients <ref type="bibr" target="#b11">(12)</ref> or recurrent HCV infection, respectively, and liver damage following liver transplantation <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b13">14)</ref>.</s><s>In view of these still preliminary studies being conducted on a rather small number of patients, we tried to define the role of APOE polymorphisms on a larger scale of patients in two independent well-characterized cohorts with chronic HCV infection, hereby correlating the different APOE genotypes and alleles with demographic, biochemical, molecular and available histological parameters of these patients.</s><s>Patients with spontaneous HCV clearance and non-HCV-associated chronic liver disease and healthy subjects were used as respective controls.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subjects</head><p><s>In total, 3 692 participants gave informed consent to this study protocol, which was approved by the Ethics Committees of the Charit e Berlin and the University of Leipzig; among them, two large and independent cohorts with 701 and 295 chronically HCV-infected patients; 179 patients with a history of spontaneous HCV clearance; 283 patients with non-HCV-associated chronic liver disease; and 2 234 subjects without a history of chronic liver disease.</s><s>The majority of chronically HCV-infected patients had been enrolled in prospective treatment studies at three different liver centres, comprising the Universities of Berlin, Frankfurt/Main and Homburg in Germany.</s><s>The diagnosis of chronic hepatitis C was based on the elevated serum transaminase levels for at least 6 months and consistently detectable serum HCV-RNA.</s><s>All patients were anti-HCV positive and negative for hepatitis B surface antigen and antibodies to human immunodeficiency virus 1 and 2. Quantitative assessment of serum RNA was performed either by a standardized quantitative reverse transcription-polymerase chain reaction assay (Amplicor Monitor HCV TM version 2.0; Roche Diagnostic system, Roche Diagnostics, Penzberg, Germany) or by the third-generation branched DNA assay (Versant Quantitative HCV RNA 3.0 Assay; Bayer Diagnostics, Emeryville, CA, USA).</s><s>HCV-RNA levels were standardized to International Units per millilitre (IU/ml) according to the formula described by Pawlotski et al. <ref type="bibr" target="#b14">(15)</ref>.</s><s>Genotyping of HCV was performed by reverse hybridisation assay (Inno LiPA HCV II, Innogenetics, Gent, Belgium).</s><s>Table <ref type="table" target="#tab_0">1</ref> summarizes all relevant demographic and biochemical data of the initial study cohort with 701 chronically HCV-infected patients which were assessed prior to therapy.</s><s>Table <ref type="table" target="#tab_0">1</ref> also depicts the liver histology from 555 liver biopsies (79%) which were available from this cohort.</s><s>Hepatic inflammation (grade) and fibrosis (stage) were classified according to the semiquantitative histological score described by Scheuer et al. <ref type="bibr" target="#b15">(16)</ref>.</s><s>Exact percentage of fatty degener-</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key points</head><p><s>Infectious HCV particles bind to low-density lipoproteins (LDL).</s><s>LDL receptors (LDLR) have been termed candidate receptors for HCV-LDL complexes.</s><s>Functional single nucleotide polymorphisms in the apolipoprotein E (APOE) gene encoding apolipoprotein E (apoE)a major structural LDL component and ligand of LDLreceptorslikely influence the course of HCV infection.</s></p><p><s>We genotyped 996 chronically HCV-infected patients; 179 patients with spontaneous HCV clearance; and 2 234 healthy controls.</s></p><p><s>We found a substantial under-representation of APOE4 alleles in chronically HCV-infected patients and a significant over-representation of APOE4 alleles in patients with spontaneous HCV clearance.</s></p><p><s>Our findings indicate a decreased susceptibility to chronic HCV infection in APOE4 allele carriers.</s><s>ated hepatocytes obtained from 430 histological reports (31%) was classified according to the following scheme: 0% (none), &lt;25%, 25-50% and &gt;50% fatty degenerated hepatocytes.</s></p><p><s>The validation cohort with 295 chronically HCVinfected comprised 161 males (54.6%) and 134 women (45.4%).</s><s>Spontaneous HCV clearance was assumed by the presence of positive HCV antibody titres but persistent negative HCV-RNA (PCR) and normal transaminase levels during the preceding 6 months.</s><s>Of the group of 179 individuals with self-limited HCV infection, 75 (41.9%)</s><s>were male and 94 (52.5%) were female.</s><s>Of the group of 283 patients with non-HCV-associated chronic liver disease, 129 (45.6%) were male and 154 (54.4%) were female; among them, patients with chronic hepatitis B infection, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis and alcoholic liver disease.</s><s>The controls investigated were blood donors from South-West and East Germany.</s><s>In total, we screened 2 234 controls (932 male, age range 18-81 years, median 50 years).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Apolipoprotein genotyping and statistical analysis</head><p><s>Commercially available kits (Qiagen, Hilden, Germany) were used to extract the DNA from EDTA blood samples.</s><s>APOE genotyping was performed by restriction fragment length polymorphism analysis as described <ref type="bibr" target="#b16">(17)</ref>.</s><s>For analysis of the control subjects, we performed melting curve analysis in a LightCycler 480 instrument (Roche Diagnostics).</s><s>PCR was performed using 0.75 U AmpliTaq Gold polymerase (Applied Biosystems, Inc. Foster City, CA, USA), 400 lM dNTPs, 1.5 mM MgCl 2 and 0.4 lM F-Primer as well as 0.1 lM R-primer in a total volume of 25 ll.</s><s>Cycle conditions were an initial denaturation for 12 min at 95°C followed by 47 cycles of 20 s denaturation at 95°C, 40 s annealing at 64°C, 90 s primer extension at 72°C and a final extension for 2 min at 72°C in an automated thermal cycler (Applied Biosystems).</s><s>Primers were synthesized according to the published nucleotide sequences (GenBank: NC_000 019.9):</s><s>F-Primer 5 0 -TTGAAGGCCTACAAATCGGAAC TG-3 0 ; R-Primer 5 0 -GCCCCGGCCTGGTACAC-3 0 .</s></p><p><s>We performed melting curve analysis using two pairs of fluorescent resonance energy transfer (FRET) probes.</s><s>FRET probes were designed and synthesized by TIB Molbiol (Berlin, Germany): Codon 112: Sensor probe 5 0 -LC640-ACATGGAGGACGTGCGCGG-3 0 , Anchor probe 5 0 -CTGCAGGCGGCGCAGGCCCGGCTGGGCG C-FL-3 0 ; Codon 158: Sensor probe 5 0 -LC610-GACCTG CAGAAGCGCCTGGC-3 0 , Anchor probe 5 0 -GCTGCGT AAGCGGCTCCTCCGCGATGCCG-FL-3 0 .</s><s>Analytical melting included the following steps: 97°C for 60 s, 45°C for 60 s and an increase to 80°C at a 0.19°C/s ramp rate.</s></p><p><s>Corresponding APOE allele frequencies are displayed as their group percentages.</s><s>Possible implications of APOE in the course of the HCV infection are expressed by odds ratios (OR) with a 95% confidence limit (CI).</s><s>Nonparametric data are expressed as median (range).</s><s>Statistical analysis was performed by contingency tables using ‫א‬ 2 statistics and Mann-Whitney tests.</s><s>All statistical calculations were performed with SPSS 11.0 software for Windows (SPSS, Inc, Chicago, IL, USA).</s><s>If not stated otherwise, all tests were twosided and P-values lower than 0.05 were considered significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>The distribution of APOE genotypes and allele frequencies differs in patients with chronic hepatitis C and control subjects without chronic liver disease In total, 701 patients with chronic HCV infection and an independent validation cohort comprising 295 additional patients with chronic HCV infection and 2 234 control subjects without chronic liver disease were included in this study.</s><s>The overall distribution of APOE genotypes and corresponding allele frequencies in the two HCV cohorts and the control subjects are depicted in Table <ref type="table" target="#tab_1">2</ref>.</s><s>There was no difference in the APOE genotype distribution between the initial HCV cohort and the validation cohort (Table <ref type="table" target="#tab_1">2</ref>), which were therefore combined for the subsequent statistical analysis.</s><s>APOE genotypes in HCV patients and controls were in Hardy-Weinberg equilibrium, but the overall distribution of APOE genotypes and APOE alleles differed significantly between the two groups (P &lt; 0.007; data not shown).</s><s>This was because of a marked over-representation of the APOE3 allele in patients with chronic hepatitis C (82.7% APOE3) compared to 78.6% APOE3 in control subjects (OR 1.052; 95% CI 1.026-1.079;</s><s>P &lt; 0.0002, Table <ref type="table" target="#tab_1">2</ref>), confirming an earlier study which already associated the APOE3 allele with an increased risk for persistent HCV infection <ref type="bibr" target="#b8">(9)</ref>.</s><s>However, our data also revealed a substantial under-representation of the APOE4 allele in patients with chronic hepatitis C (10.5% APOE4) compared to 13.0% APOE4 in control subjects (OR 0.780; 95% CI 0.671-0.906;</s><s>P = 0.001, Table <ref type="table" target="#tab_1">2</ref>), suggesting a protective effect of APOE4 in the course of HCV infection.</s><s>Consistent with this observation, subjects carrying at least one APOE4 allele (APOE4+ genotypes: e2 e4, e3 e4, e4 e4) were significantly under-represented in chronically HCV-infected patients (19.4% APOE4+) compared to 24.5% APOE4+ in control subjects (OR 0.791; 95% CI 0.684-0.916;</s><s>P = 0.001, Table <ref type="table" target="#tab_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Association of APOE4 with self-limited HCV infection</head><p><s>Genotyping of 179 patients with self-limited HCV infection revealed a significant over-representation of the APOE4 allele (17.6% APOE4) compared to chronically HCV-infected patients (OR 1.727; 95% CI 1.332-2.238;</s><s>P &lt; 0.00009, Table <ref type="table" target="#tab_2">3</ref>) and control subjects (OR 1.346; 95% CI 1.063-1.706;</s><s>P = 0.016, data not shown).</s><s>APOE4+ genotypes were also significantly over-represented in the group of patients with spontaneous HCV resolution (34.1% APOE4+) compared to chronically HCV-infected patients (OR 1.759; 95% CI 1.384-2.235,</s><s>P &lt; 0.00002, Table <ref type="table" target="#tab_2">3</ref>) and control subjects (OR 1.392; 95% CI 1.121-1.728,</s><s>P = 0.005, data not shown), providing further evidence of an increased likelihood of a self-limited HCV infection.</s><s>To exclude any sampling effects because of the independence of the HCV patients and the control subjects, and to confirm the HCV specificity of our present observation, we also genotyped 283 patients at comparable risk for HCV exposure but with non-HCV-associated chronic liver disease.</s><s>These patients were presented with an APOE genotype and allele distribution (26.9%</s><s>APOE4+ respectively 14% APOE4 allele, Table <ref type="table" target="#tab_2">3</ref>) which was very similar to the control group (P = 0.421 for APOE4+ respectively P = 0.598 for APOE4, data not shown).</s><s>However, the APOE4+ genotype and the APOE4 allele distribution in 283 patients with non-HCV-associated chronic liver disease also significantly differed from chronically HCV-  <ref type="table" target="#tab_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparison of relevant clinical and histological parameters in chronically HCV-infected APOE4+ and APOE4À patients</head><p><s>The comparison of relevant clinical and histological data in APOE4+ and APOE4À patients with chronic HCV infection revealed that only total plasma cholesterol levels differed significantly between these two groups, showing higher mean cholesterol levels in APOE4+ allele carriers (Table <ref type="table" target="#tab_3">4</ref> and Fig. <ref type="figure">S1</ref>).</s><s>Table <ref type="table" target="#tab_4">5</ref> compares characteristic histological findings in chronically HCV-infected patients with respect to their APOE4 allele carrier status.</s></p><p><s>In patients with mild liver disease (i.e.</s><s>inflammation grade ≤1 or fibrosis stage ≤1), a significant higher APOE4 allele proportion was found.</s><s>This association was even more pronounced when analysis was restricted to HCV type 1-infected patients (14% APOE4 allele frequency in inflammation grade ≤1 vs. 9.1% in grade &gt;1; OR 0.57, 0.36 -0.9, P = 0.016; data not shown).</s><s>However, when we compared the APOE4 allele status of all patients with more advanced liver disease (i.e.</s><s>inflammation grade &gt;2 or fibrosis stage &gt;2), no significant differences in the APOE4 allele frequency could be observed.</s><s>The degree of liver steatosis in APOE4 allele carriers was significantly reduced compared to patients without APOE4 allele.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This study investigated the role of APOE polymorphism in two large and independent cohorts of 701 and 295 chronically HCV-infected patients.</s><s>The under-representation of APOE4 allele carriers in patients with chronic hepatitis C compared to the over-representation of APOE4 allele carriers in patients who spontaneously cleared HCV infection suggests a protective role of APOE4 in the course of HCV infection.</s><s>This interpretation is further supported by the fact that the observed frequency of APOE4 allele-carrying patients (n = 140) differed significantly from predictions by the Hardy-Weinberg equation (n = 158 expected) whereas the APOE genotype distribution in our control group was comparable to data published for the general population  <ref type="table" target="#tab_2">3</ref>) revealed no significant differences compared to the control group (data not shown).</s></p><p><s>To understand the suggested protective function of the APOE4 allele, insight into the complex relationship between HCV infection and the lipid metabolism within the human host is crucial <ref type="bibr" target="#b23">(23)</ref>.</s><s>Thus, infectious HCV particles can bind to plasma lipoproteins such as LDL and VLDL which enables them to interact with the ApoB/E-LDL receptor on hepatocytes.</s><s>It is believed that this mechanism promotes HCV cell entry <ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref><ref type="bibr" target="#b4">(5)</ref><ref type="bibr" target="#b5">(6)</ref>.</s><s>Moreover, the association of HCV E2 with LDL has been reported to enhance hepatocellular binding of LDL <ref type="bibr" target="#b24">(24)</ref> and therefore might contribute to the epidemiological observation of decreased serum cholesterol levels in chronically HCV-infected patients.</s><s>The cellular ApoB/E receptor expression itself is regulated by the human serum lipoprotein concentration.</s><s>Thus, on the one hand, APOE polymorphism could exert an indirect effect on LDL receptor expression as increased binding and internalization of lipoproteins, which was demonstrated for APOE4 allele carriers <ref type="bibr" target="#b25">(25,</ref><ref type="bibr" target="#b26">26)</ref>, is thought to cause downregulation of cellular LDL receptors with subsequent hyperbetalipoproteinemia and hypercholesterolaemia <ref type="bibr" target="#b27">(27)</ref><ref type="bibr" target="#b28">(28)</ref><ref type="bibr" target="#b29">(29)</ref><ref type="bibr" target="#b30">(30)</ref>.</s><s>This association of increased cholesterol levels in APOE4 carriers was also demonstrated in our APOE4-carrying population with chronic hepatitis C. On the other hand, the APOE4-induced hyperbetalipoproteinemia could directly interfere with the LDL receptormediated cellular virus uptake due to enforced competition between free betalipoproteins and viruslipoprotein particles for free LDL receptor sites <ref type="bibr" target="#b4">(5)</ref>.</s><s>Thus, these functional properties in lipid metabolism related to APOE polymorphism provide a reasonable explanation that APOE4-related downregulation of LDL receptors can exert a protective effect on HCV infection.</s><s>Moreover, ApoE protein levels, which have been shown to mediate evasion from hepatitis C-neutralizing antibodies in a recent study <ref type="bibr" target="#b31">(31)</ref>, appear to be the lowest in APOE4 allele carriers <ref type="bibr" target="#b18">(19,</ref><ref type="bibr" target="#b32">32)</ref>.</s><s>Therefore, HCV infection might be less likely to evade neutralizing antibodies in these patients.</s></p><p><s>Several limitations of the present candidate gene study must be acknowledged.</s><s>First, previous genomewide association studies could not confirm a major role of APOE in the course of HCV infection.</s><s>Second, chronic HCV infection was also found in homozygous APOE4 allele carriers in the present study.</s><s>Taken together, the protective effect of APOE4 might be rather limited as compared to the well-established effect of IL28B polymorphisms.</s><s>IL28B genotyping was available in 751 patients with chronic HCV infection and APOE was not in linkage disequilibrium with the IL28B rs12979860 polymorphism.</s><s>However, it was interesting to note that we detected the lowest proportion of APOE4 allele carriers in patients with a history of intravenous drug abuse (7.2% vs. 11.3%,</s><s>P = 0.045; data not shown), suggesting that APOE4 might be relevant in the case of low viral contamination, i.e. in HCV-contaminated needle sharing.</s></p><p><s>Another interesting observation made by other groups <ref type="bibr" target="#b17">(18,</ref><ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b33">33,</ref><ref type="bibr" target="#b34">34)</ref> may deserve further attention in the future.</s><s>These authors pointed out that there exists a clear decreasing north-south gradient of the APOE4 allele frequency through European countries which is inversely correlated with the prevalence of HCV infection <ref type="bibr" target="#b36">(35)</ref>.</s><s>The APOE4 allele was also identified as a strong genetic risk factor for the development of Alzheimer's disease in patients suffering from HSV infection <ref type="bibr" target="#b37">(36)</ref>.</s><s>Chronic liver disorders of different aetiologies have been also studied in this respect.</s><s>Corpechot et al. <ref type="bibr" target="#b38">(37)</ref> discussed that patients with primary biliary cirrhosis may have a more severe course of the disease and are also less sensitive to therapeutic interventions when carrying the APOE4 allele.</s><s>In contrast to the observation by Wozniak et al. <ref type="bibr" target="#b9">(10)</ref>, APOE4 allele frequencies in our chronic hepatitis C study population did not differ significantly with respect to the severe fibrosis stage (≤2 vs. †Only histological reports with notification of the exact percentage of fatty degenerated hepatocytes were considered.</s><s>APOE, apolipoprotein E (genotype); CI, confidence limit; OR, odds ratios.</s></p><p><s>&gt;2) or inflammation grade (≤2 vs. 3).</s><s>One reason for these discrepant findings may be that different scores for histological classification were used in these studies (Knodell score vs. Scheuer score).</s><s>One should also point out that numbers of patients varied greatly in these two studies.</s><s>However, in our analysis comparing APOE4 vs. non-E4 allele carriers we could indeed observe a higher proportion of APOE4 allele carriers in patients with documented mild fibrosis or inflammation (stage and grade ≤1).</s></p><p><s>In conclusion, the under-representation of APOE4 allele carriers in patients with chronic hepatitis C compared to the over-representation of APOE4 allele carriers in patients who spontaneously cleared HCV infection suggests a protective role of the APOE4 allele in the course of HCV infection.</s><s>These APOE4 allelerelated data give, for the first time, a convincing hint that this allele is not only associated with negative clinical aspects as for instance increased risk for atherosclerosis and Alzheimer's disease but may also convey protective genetic functions.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Relevant demographic, biochemical, molecular and histological data of 701 study participants with chronic hepatitis C infection</s></p></div></figDesc><table><row><cell></cell><cell>Patients with</cell><cell></cell></row><row><cell></cell><cell>chronic hepatitis</cell><cell></cell></row><row><cell></cell><cell>C</cell><cell></cell></row><row><cell>Demography</cell><cell></cell><cell></cell></row><row><cell>Male/female (% male)</cell><cell>391/310</cell><cell>(56%)</cell></row><row><cell>Age (years)*</cell><cell>48.7 AE 0.31</cell><cell>(19-82)</cell></row><row><cell cols="2">Risk factors for hepatitis C infection (%)</cell><cell></cell></row><row><cell>Intravenous drug abuse</cell><cell>145</cell><cell>(20.7%)</cell></row><row><cell>Recipient of blood products</cell><cell>165</cell><cell>(23.5%)</cell></row><row><cell>Others †</cell><cell>30</cell><cell>(4.3%)</cell></row><row><cell>Sporadic/unknown</cell><cell>361</cell><cell>(51.5%)</cell></row><row><cell>Biochemistry* ‡</cell><cell></cell><cell></cell></row><row><cell>ALT</cell><cell>62.4 AE 2.0</cell><cell>(6-422)</cell></row><row><cell>AST</cell><cell>36.5 AE 0.9</cell><cell>(8-329)</cell></row><row><cell>AP</cell><cell>115.7 AE 1.9</cell><cell>(12-853)</cell></row><row><cell>GGT</cell><cell>43.5 AE 2.3</cell><cell>(4-341)</cell></row><row><cell>Ferritin</cell><cell>221.7 AE 11.1</cell><cell>(6-2 230)</cell></row><row><cell>Plasma cholesterol</cell><cell>178.7 AE 2.3</cell><cell>(79-355)</cell></row><row><cell>HCV genotype</cell><cell cols="2">434; 52; 154; 16; 2; 43</cell></row><row><cell>(1; 2; 3; 4; 6; not determined)</cell><cell></cell><cell></cell></row><row><cell>Viremia (910 6 IU/ml)*</cell><cell cols="2">2.9 AE 0.3 (0.008-98)</cell></row><row><cell>Liver histology §</cell><cell></cell><cell></cell></row><row><cell>Inflammation (grade; n = 555)</cell><cell></cell><cell></cell></row><row><cell>Absent</cell><cell>2</cell><cell>(0.4%)</cell></row><row><cell>Minimal</cell><cell>14</cell><cell>(2.5%)</cell></row><row><cell>Mild</cell><cell>187</cell><cell>(33.7%)</cell></row><row><cell>Moderate</cell><cell>277</cell><cell>(49.9%)</cell></row><row><cell>Severe</cell><cell>75</cell><cell>(13.5%)</cell></row><row><cell>Fibrosis (stage; n = 555)</cell><cell></cell><cell></cell></row><row><cell>Absent</cell><cell>22</cell><cell>(4.0%)</cell></row><row><cell>Mild without septa</cell><cell>176</cell><cell>(31.7%)</cell></row><row><cell>Moderate with few septa</cell><cell>192</cell><cell>(34.6%)</cell></row><row><cell>Numerous septa, no cirrhosis</cell><cell>121</cell><cell>(21.8%)</cell></row><row><cell>Cirrhosis</cell><cell>44</cell><cell>(7.9%)</cell></row><row><cell>Steatosis (%; n = 215) ¶</cell><cell></cell><cell></cell></row><row><cell>None</cell><cell>39</cell><cell>(18.1%)</cell></row><row><cell>&lt;25</cell><cell>78</cell><cell>(36.3%)</cell></row><row><cell>25-50</cell><cell>65</cell><cell>(30.2%)</cell></row><row><cell>&gt;50</cell><cell>33</cell><cell>(15.3%)</cell></row><row><cell>*Mean AE SEM (range).</cell><cell></cell><cell></cell></row><row><cell cols="3">†Including occupational exposure, sexual transmission, skin tattoos,</cell></row><row><cell>treatment for bilharziosis.</cell><cell></cell><cell></cell></row><row><cell cols="3">‡Upper normal limit of laboratory data (ULN, measured at 25°C): ALT,</cell></row><row><cell cols="3">19 U/L (female), 23 U/L (male); AST, 18 U/L (female), 21 U/L (male);</cell></row><row><cell cols="3">AP, 60-180 U/L (female/male), GGT, 18 U/L (female); 28 U/L (male);</cell></row><row><cell cols="3">Ferritin, 10-200 lg/L (female), 30-300 lg/L (male); cholesterol,</cell></row><row><cell>200 mg/L (female/male)</cell><cell></cell><cell></cell></row><row><cell cols="3">§Histological classification according to the Scheuer score (16).</cell></row><row><cell cols="3">¶Only histological reports with notification of the exact percentage of</cell></row><row><cell cols="2">fatty degenerated hepatocytes were considered.</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>APOE genotype proportions in two independent cohorts of patients with chronic hepatitis C and healthy controls</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell cols="2">Chronic hepatitis</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">Chronic hepatitis C</cell><cell cols="2">C cohort-2</cell><cell></cell><cell>Healthy</cell><cell>controls</cell><cell></cell><cell></cell><cell></cell></row><row><cell>APOE</cell><cell cols="2">cohort-1 (n = 701)</cell><cell cols="2">(n = 295)</cell><cell>P</cell><cell cols="2">(n = 2 234)</cell><cell>OR</cell><cell>95% CI</cell><cell>P</cell></row><row><cell>Genotype</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>e2 e2</cell><cell>1</cell><cell>(0.1%)</cell><cell>1</cell><cell>(0.3%)</cell><cell>n.s.</cell><cell>11</cell><cell>(0.5%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>e2 e3</cell><cell>80</cell><cell>(11.4%)</cell><cell>44</cell><cell>(14.9%)</cell><cell>n.s.</cell><cell>299</cell><cell>(13.4%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>e2 e4</cell><cell>7</cell><cell>(1.0%)</cell><cell>7</cell><cell>(2.4%)</cell><cell>n.s.</cell><cell>53</cell><cell>(2.4%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>e3 e3</cell><cell>480</cell><cell>(68.5%)</cell><cell>197</cell><cell>(66.8%)</cell><cell>n.s.</cell><cell>1 377</cell><cell>(61.6%)</cell><cell>1.103</cell><cell>1.045-1.164</cell><cell>0.001</cell></row><row><cell>e3 e4</cell><cell>126</cell><cell>(18.0%)</cell><cell>43</cell><cell>(14.6%)</cell><cell>n.s.</cell><cell>457</cell><cell>(20.5%)</cell><cell>0.829</cell><cell>0.707-0.973</cell><cell>0.021</cell></row><row><cell>e4 e4</cell><cell>7</cell><cell>(1.0%)</cell><cell>3</cell><cell>(1.0%)</cell><cell>n.s.</cell><cell>37</cell><cell>(1.7%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>APOE4+*</cell><cell>140</cell><cell>(20.0%)</cell><cell>53</cell><cell>(18.0%)</cell><cell>n.s.</cell><cell>547</cell><cell>(24.5%)</cell><cell>0.791</cell><cell>0.684-0.916</cell><cell>0.001</cell></row><row><cell>APOE4À †</cell><cell>561</cell><cell>(80.0%)</cell><cell>242</cell><cell>(82.0%)</cell><cell></cell><cell>1 687</cell><cell>(75.5%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Allele</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>e2</cell><cell>89</cell><cell>(6.3%)</cell><cell>53</cell><cell>(9.0%)</cell><cell>0.045</cell><cell>374</cell><cell>(8.4%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>e3</cell><cell>1 166</cell><cell>(83.2%)</cell><cell>481</cell><cell>(81.5%)</cell><cell>n.s.</cell><cell>3 510</cell><cell>(78.6%)</cell><cell>1.052</cell><cell>1.026-1.079</cell><cell>0.0001472</cell></row><row><cell>e4</cell><cell>147</cell><cell>(10.5%)</cell><cell>56</cell><cell>(9.5%)</cell><cell>n.s.</cell><cell>584</cell><cell>(13.0%)</cell><cell>0.780</cell><cell>0.671-0.906</cell><cell>0.001</cell></row></table><note><p><s>*Study participants carrying the apolipoprotein E4 allele: APOE4+: e2 e4, e3 e4, e4 e4.†Study participants without the apolipoprotein E4 allele: APOE4À: e2 e2, e2 e3, e3 e3.APOE, apolipoprotein E (genotype), CI, confidence limit; OR, odds ratios.infected</s><s>patients (OR 1.386; 95% CI 1.101-1.745;</s><s>P = 0.008 for APOE4+ genotype; respectively OR 1.370; 95% CI 1.075-1.746;</s><s>P = 0.012 for the APOE4 allele, Table</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Comparison of APOE proportions in patients with chronic hepatitis C, spontaneous HCV clearance and non-HCV-associated chronic liver disease</s></p></div></figDesc><table><row><cell></cell><cell>Chronic hepatitis</cell><cell>Spontaneous</cell><cell></cell><cell></cell><cell></cell><cell>Non-HCV liver</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>C cohort-1 + 2</cell><cell>HCV clearance</cell><cell></cell><cell></cell><cell></cell><cell>disease</cell><cell></cell><cell></cell><cell></cell></row><row><cell>APOE</cell><cell>(n = 996)</cell><cell>(n = 179)</cell><cell>OR</cell><cell>95% CI</cell><cell>P</cell><cell>(n=283)</cell><cell>OR</cell><cell>95% CI</cell><cell>P</cell></row><row><cell>Genotype</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>e2e 2</cell><cell>2 (0.2%)</cell><cell>0 (0.0%)</cell><cell></cell><cell></cell><cell>n.s.</cell><cell>0 (0.0%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>e2 e3</cell><cell>124 (12.5%)</cell><cell>25 (14.0%)</cell><cell></cell><cell></cell><cell>n.s.</cell><cell>29 (10.2%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>e2 e4</cell><cell>14 (1.4%)</cell><cell>8 (4.5%)</cell><cell cols="3">3.180 1.354-7.469 0.012</cell><cell>6 (2.1%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>e3 e3</cell><cell>677 (67.9%)</cell><cell cols="5">93 (52.0%) 0.764 0.660-0.886 0.00004199 178 (62.9%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>e3 e4</cell><cell>169 (17.0%)</cell><cell cols="4">51 (28.5%) 1.679 1.282-2.199 0.0004189</cell><cell cols="4">67 (23.7%) 1.395 1.086-1.792 0.012</cell></row><row><cell>e4 e4</cell><cell>10 (1.0%)</cell><cell>2 (1.1%)</cell><cell></cell><cell></cell><cell>n.s.</cell><cell>3 (1.1%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>APOE4+*</cell><cell>193 (19.4%)</cell><cell cols="4">61 (34.1%) 1.759 1.384-2.235 0.00001959</cell><cell cols="4">76 (26.9%) 1.386 1.101-1.745 0.008</cell></row><row><cell>APOE4À †</cell><cell cols="2">803 (80.6%) 118 (65.9%)</cell><cell></cell><cell></cell><cell></cell><cell>207 (73.1%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Allele</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>e2</cell><cell>142 (7.1%)</cell><cell>33 (9.2%)</cell><cell></cell><cell></cell><cell>n.s.</cell><cell>35 (6.2%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>e3</cell><cell cols="5">1 647 (82.7%) 262 (73.2%) 0.885 0.829-0.945 0.0000334</cell><cell>452 (79.9%)</cell><cell></cell><cell></cell><cell>n.s.</cell></row><row><cell>e4</cell><cell>203 (10.2%)</cell><cell cols="4">63 (17.6%) 1.727 1.332-2.238 0.00008304</cell><cell cols="2">79 (14.0%) 1.37</cell><cell cols="2">1.075-1.746 0.012</cell></row><row><cell cols="6">*Study participants carrying the apolipoprotein E4 allele: APOE4+: e2 e4, e3 e4, e4 e4.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">†Study participants without the apolipoprotein E4 allele: APOE4À: e2 e2, e2 e3, e3 e3.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">APOE, apolipoprotein E (genotype); CI, confidence limit; OR, odds ratios.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Relationship between APOE4 allele carrier status and demographic and biochemical characteristics in 701 patients with chronic hepatitis C</s></p></div></figDesc><table><row><cell>Parameters* †</cell><cell>APOE4(À)</cell><cell>APOE4(+)</cell><cell>P</cell></row><row><cell>Age</cell><cell>48.6 AE 0.3</cell><cell>49.2 AE 0.9</cell><cell>0.461</cell></row><row><cell>BMI</cell><cell>24.9 AE 0.2</cell><cell>24.5 AE 0.4</cell><cell>0.816</cell></row><row><cell>ALT</cell><cell>63.3 AE 1.5</cell><cell>54.6 AE 3.3</cell><cell>0.129</cell></row><row><cell>AST</cell><cell>36.8 AE 0.9</cell><cell>34.2 AE 3.2</cell><cell>0.112</cell></row><row><cell>GGT</cell><cell>44.0 AE 1.7</cell><cell>38.6 AE 4.0</cell><cell>0.556</cell></row><row><cell>Ferritin</cell><cell>226.3 AE 12.2</cell><cell>186.8 AE 22.2</cell><cell>0.409</cell></row><row><cell>Total cholesterol</cell><cell>177.5 AE 1.7</cell><cell>189.1 AE 4.4</cell><cell>0.009</cell></row><row><cell>Viremia (910 6 IU/ml)</cell><cell>2.9 AE 0.2</cell><cell>3.0 AE 0.4</cell><cell>0.232</cell></row><row><cell>*Mean AE SEM (range).</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">†Upper normal limit of laboratory data (ULN, measured at 25°C): ALT,</cell></row><row><cell cols="4">19 U/L (female), 23 U/L (male); AST, 18 U/L (female), 21 U/L (male);</cell></row><row><cell cols="4">AP, 60-180 U/L (female/male), GGT, 18 U/L (female); 28 U/L (male);</cell></row><row><cell cols="4">Ferritin, 10-200 lg/L (female), 30-300 lg/L (male); total cholesterol,</cell></row><row><cell>200 mg/L (female/male).</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">ALT, alanine aminotransferase; APOE, apolipoprotein E (genotype);</cell></row><row><cell cols="4">AST, aspartate aminotransferase; BMI, body mass index; GGT, c-gluta-</cell></row><row><cell>myltransferase.</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Relationship between APOE4 allele carrier status and histological damage in 555 patients with chronic hepatitis C</s></p></div></figDesc><table><row><cell></cell><cell>APOE4 allele</cell><cell>OR</cell><cell>95% CI</cell><cell>P</cell></row><row><cell cols="2">Inflammation (grade)*</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;1</cell><cell>13.5</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&gt;1</cell><cell>9.2</cell><cell>0.43</cell><cell>0.44-0.95</cell><cell>0.027</cell></row><row><cell>&lt;2</cell><cell>11.1</cell><cell></cell><cell></cell><cell></cell></row><row><cell>3</cell><cell>8.7</cell><cell>0.76</cell><cell>0.41-1.38</cell><cell>0.365</cell></row><row><cell cols="2">Fibrosis (stage)*</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;1</cell><cell>13.4</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&gt;1</cell><cell>9.4</cell><cell>0.67</cell><cell>0.46-0.98</cell><cell>0.041</cell></row><row><cell>≤2</cell><cell>11.4</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&gt;2</cell><cell>9.4</cell><cell>0.81</cell><cell>0.52-1.24</cell><cell>0.323</cell></row><row><cell>Steatosis (%) †</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;25</cell><cell>14.4</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&gt;25</cell><cell>8.2</cell><cell>0.53</cell><cell>0.29-1.0</cell><cell>0.050</cell></row><row><cell>None</cell><cell>17.9</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Steatosis</cell><cell>9.3</cell><cell>0.47</cell><cell>0.24-0.91</cell><cell>0.025</cell></row></table><note><p><s>(16)tological classification according to the Scheuer score(16).</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Liver International (2016) © 2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgement</head><p><s>The authors thank Barbara Malik for excellent logistical and technical support.</s></p><p><s>Financial support: This work was supported by the German Network of Competence for Viral Hepatitis (Hep Net).</s></p><p><s>Conflict of interest: The authors do not have any disclosures to report.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head><p><s>Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1111/liv.13094/suppinfo</s><s>Liver International (2016)</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Association of hepatitis C virus in human sera with beta-lipoprotein</title>
		<author>
			<persName><forename type="first">R</forename><surname>Thomssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bonk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Propfe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Microbiol Immunol</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="page" from="293" to="300" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Characterization of low-and very-low-density hepatitis C virus RNA-containing particles</title>
		<author>
			<persName><forename type="first">P</forename><surname>Andre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Komurian-Pradel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Deforges</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Virol</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="6919" to="6928" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wunschmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Medh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Klinzmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">N</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Stapleton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Virol</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="10055" to="10062" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor</title>
		<author>
			<persName><forename type="first">V</forename><surname>Agnello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Abel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Elfahal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Knight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">X</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="12766" to="12771" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Low density lipoprotein receptor as a candidate receptor for hepatitis C virus</title>
		<author>
			<persName><forename type="first">M</forename><surname>Monazahian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bohme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bonk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Virol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="223" to="229" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption</title>
		<author>
			<persName><forename type="first">R</forename><surname>Germi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Crance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Garin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Virol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="206" to="215" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Apolipoprotein E: an important gene and protein to follow in laboratory medicine</title>
		<author>
			<persName><forename type="first">G</forename><surname>Siest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pillot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Regis-Bailly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1068" to="1086" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>Pt 1</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kuhlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Minihane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Huebbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rimbach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lipids Health Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">8</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Bassendine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Norris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="715" to="718" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Wozniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Itzhaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Faragher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="456" to="463" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1</title>
		<author>
			<persName><forename type="first">T</forename><surname>Mueller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gessner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sarrazin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1592" to="1593" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Gochee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Purdie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychosomatics</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="49" to="57" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Low fibrosis progression of recurrent hepatitis C in apolipoprotein E epsi-lon4 carriers: relationship with the blood lipid profile</title>
		<author>
			<persName><forename type="first">C</forename><surname>Fabris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Toniutto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bitetto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Int</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1128" to="1135" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment</title>
		<author>
			<persName><forename type="first">P</forename><surname>Toniutto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fabris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fumo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="428" to="433" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Standardization of hepatitis C virus RNA quantification</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pawlotsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bouvier-Alias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hezode</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="654" to="659" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Classification of chronic viral hepatitis: a need for reassessment</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Scheuer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="372" to="374" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">In an epidemiological sample the apolipoprotein E4 allele is associated to dementia and loss of memory function only in the very old</title>
		<author>
			<persName><forename type="first">R</forename><surname>Gessner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Reischies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kage</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">222</biblScope>
			<biblScope unit="page" from="29" to="32" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses</title>
		<author>
			<persName><forename type="first">G</forename><surname>Siest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bertrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Herbeth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem Lab Med</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="841" to="852" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">F</forename><surname>Schiele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Bacquer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vincent-Viry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project</title>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="475" to="488" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E</title>
		<author>
			<persName><forename type="first">W</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ehrenhaft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Griesser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem Lab Med</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1123" to="1131" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Apolipoprotein E polymorphism and coronary artery disease</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Menzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Kladetzky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Assmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arteriosclerosis</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="310" to="315" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Genetic control of human apolipoprotein E polymorphism: comparison of one-and two-dimensional techniques of isoprotein analysis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Utermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Steinmetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Weber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Genet</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="344" to="351" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Pathog</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">e108</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wunschmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Stipp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Hemler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Stapleton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="1058" to="1067" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bohnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pillot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Visvikis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sabolovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Siest</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Lipid Res</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1316" to="1324" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Mamotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sturm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Foo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Van Bockxmeer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol</title>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="page" from="E553" to="557" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>Pt 1</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in humans</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Gregg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Brewer</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="B28" to="32" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Sing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Davignon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="268" to="285" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Apolipoprotein E polymorphism and atherosclerosis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Davignon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Gregg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Sing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arteriosclerosis</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1" to="21" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apoprotein E phenotypes</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Miettinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gylling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vanhanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ollus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arterioscler Thromb</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1044" to="1052" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Apolipoprotein E mediates evasion from hepatitis C Virus neutralizing antibodies</title>
		<author>
			<persName><forename type="first">C</forename><surname>Fauvelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Felmlee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Crouchet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="206" to="217" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vincent-Viry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schiele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gueguen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="957" to="965" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a &apos;thrifty&apos; allele?</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Corbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Scacchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Hum Genet</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="301" to="310" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>Pt 4</note>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">U</forename><surname>Gerdes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Klausen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sihm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Faergeman</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world</title>
	</analytic>
	<monogr>
		<title level="j">Genet Epidemiol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="155" to="167" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research</title>
		<author>
			<persName><forename type="first">S</forename><surname>Touzet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kraemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Colin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="667" to="678" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Herpes simplex virus type 1 in brain and risk of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Itzhaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="page" from="241" to="244" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis?</title>
		<author>
			<persName><forename type="first">C</forename><surname>Corpechot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Benlian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Barbu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="324" to="328" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
